Status on FDA Advisory Committee Vote on Roxadustat in Anemia of Chronic Kidney Disease

16 July 2021 -- The Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anemia in chronic...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news